Seqens Seqens

X
[{"orgOrder":0,"company":"Biolink LifeSciences","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioLink Life Sciences, Charak Foundation and KARE Biosciences Announce Contract For Developing a Novel Treatment of COVID Pneumonia And Prevention of Long COVID","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III"}]

Find Clinical Drug Pipeline Developments & Deals by Biolink LifeSciences

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Ramatroban (KARE 101), a dual blocker of thromboxane and prostanoid receptors, has demonstrated efficacy in animal models of respiratory dysfunction, atherosclerosis, thrombosis, and sepsis, and evidence for rapid relief of dyspnea and hypoxemia in COVID-19 pneumonia.

            Lead Product(s): Ramatroban

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: KARE 101

            Highest Development Status: Phase II/ Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: BARDA

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Funding October 05, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY